The Shotlee Journal
Browse Shotlee articles about Weight Management.
Showing 9 / 872 Weight Management articles
Serena Williams' 2026 Super Bowl ad spotlighted her GLP-1 weight-loss journey, fueling massive online searches for drugs like Ozempic and Wegovy. With ads bombarding daily life and insurance often falling short, a booming online market offers cheaper options—but at what risk? Here's what you need to know to safely buy GLP-1 drugs online.
In 2026, the gut reset era is transforming weight loss by linking it inseparably to digestive health and metabolism. No longer isolated goals, bloating, slow metabolism, and weight gain are addressed holistically for lasting results. From microbiome breakthroughs to personalized tech tools, this integrated approach promises better outcomes.
Content creator Aishwarya Mohanraj's candid video about dropping from 74kg to 52kg in six months on Mounjaro has spotlighted the injectable drug. Amid PCOS and hypothyroidism challenges, her story shifts focus from Ozempic hype. But experts warn: pair it with lifestyle changes or risk weight regain.
The hype around Mounjaro's weight loss results is real, but so is 'Mounjaro face'—sharper yet tired-looking facial changes from rapid fat loss. Dermatologists and surgeons report more patients with hollowed cheeks and sagging skin seeking help. Experts reveal why it occurs and essential prevention strategies focusing on nutrition and skincare.
India's pharmaceutical market (IPM) surged 10.1% year-on-year in March 2026, with anti-diabetic therapies leading at 15.5% growth thanks to generic semaglutide entries. The GLP-1 agonist segment exploded to Rs 15.8 billion in MAT March, nearly tripling YoY. Ind-Ra forecasts sustained 9-10% IPM growth in FY27 amid chronic therapy dominance.
A 32-year-old bride-to-be turned to Wegovy for wedding weight loss, only to face black tongue, unbearable stomach pain, and gallbladder removal. Sarah-Jayne Crawford's ordeal highlights hidden dangers of semaglutide injections. Despite initial success, severe side effects led to emergency surgery.
MSN Laboratories has launched Semabest, its affordable generic version of semaglutide, in the Indian market after CDSCO approval. Priced nearly 50% lower than the branded drug and available in pre-filled pens, it promises comparable efficacy in HbA1c reduction, glucose control, and weight loss. This move aims to address India's diabetes crisis affecting 90 million people.
While most people on GLP-1 medications like Wegovy experience dramatic weight loss, 10-15% are non-responders. Emerging research shows these drugs still deliver benefits for liver disease, heart health, and more—independent of the scale. A new study from Dr. Daniel Drucker's lab uncovers why.
Stanford Medicine scientists have pinpointed BRP, a naturally occurring peptide dubbed 'natural Ozempic' that slashes appetite and body weight in animal studies without common semaglutide side effects like nausea or constipation. Powered by AI, this discovery targets the brain's hypothalamus for precise metabolic control. Could it offer a safer path to obesity treatment?
